Intra-cellular therapies reports first quarter 2021 financial results and provides corporate update

Caplyta supplemental new drug applications (sndas) for the treatment of bipolar depression in adults as both monotherapy and adjunctive treatment with lithium or valproate have been accepted for review by the fda, with a pdufa target action date of december 17, 2021.
ITCI Ratings Summary
ITCI Quant Ranking